Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

ConditionHepatocellular Carcinoma

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-75

SponsorChen Xiaoping

About this trial

For early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection. However, ablation is demanding on the surgeon and patients often face early recurrence if ablation is not complete. Therefore, it is necessary to find reasonable adjuvant treatment to consolidate the effect of microwave therapy.

Eligibility criteria

Qualifiers

Aged 18-75 years

Pathological type is HCC, BCLC stage 0-A

No extrahepatic HCC

No radiographic recurrence at 2-4 weeks after ablation

Disqualifiers

Any history of other malignant tumors or recurrent HCC

Any preoperative treatment for HCC including local and systemic therapy

Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency

Any persistent serious ablation-related complications

Trial design

Treatments tested in this trial

PD-1 Inhibitors

Treatment groups

200 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Chen Xiaoping

Lead sponsor

Tongji Hospital

Sponsor institution

Source ClinicalTrials.gov